AMRN - Amarin Corporation plc

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
17.79
+0.40 (+2.30%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close17.39
Open17.28
Bid17.72 x 1800
Ask17.82 x 4000
Day's Range17.15 - 18.01
52 Week Range2.35 - 23.34
Volume5,203,596
Avg. Volume7,259,579
Market Cap5.883B
Beta (3Y Monthly)0.33
PE Ratio (TTM)N/A
EPS (TTM)-0.38
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est33.20
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    Vascepa® to Be Featured in Multiple Scientific Sessions at the National Lipid Association Annual Meeting

    Amarin Corporation plc (AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that Vascepa® (icosapent ethyl) and its landmark cardiovascular outcomes trial, REDUCE-IT™ (Reduction of Cardiovascular Events With EPA - Intervention Trial), is scheduled to be featured prominently at the National Lipid Association (NLA) Scientific Sessions in Miami, May 16-19. One of three late-breaker sessions at this annual meeting, on Saturday, May 18, 4:40-4:50 p.m. ET, is devoted to an encore presentation of the unprecedented results of the REDUCE-IT cardiovascular outcomes study by Christie Ballantyne, MD, Vice Chair of Research at the Baylor College of Medicine.

  • Thomson Reuters StreetEvents12 days ago

    Edited Transcript of AMRN earnings conference call or presentation 1-May-19 11:30am GMT

    Q1 2019 Amarin Corporation PLC Earnings Call

  • Why Did Amarin (AMRN) Stock Sink After Earnings? Analysts Explain
    SmarterAnalyst13 days ago

    Why Did Amarin (AMRN) Stock Sink After Earnings? Analysts Explain

    Last week, anti-cholesterol drugmaker Amarin (AMRN) reported a better-than-expected $0.07-per-share loss on $73.3 million in sales -- also better than expected, and up 67% year over year on strong sales of its Vascepa fish oil pill. And yet, the stock plunged nearly 6% after results came out.Wall Street thinks that was a mistake -- and perhaps, an opportunity.To see why, let's take a quick look at two reactions to the earnings report from two different Wall Street analysts. We'll begin with Jefferies.Jefferies analyst Michael Yee makes no bones about it: "Q1 was a beat." And yet, the analyst notes that given strength in "scripts" written for Amarin products in Q1, some analysts were actually looking for Amarin to report even better sales than the $73 million it eventually reported -- sales of as much as $75 million to $80 million. Yet, Yee argues that Q1 sales could in fact have reached "$75-80M" had Amarin had enough product on hand to meet demand. (The analyst cites inventory "drawdown" in the quarter as evidence that the company didn't have enough product on hand to meet all the demand it encountered in Q1).In fact, says Yee, "true 'demand' is more like $80-85M" and, once Amarin makes enough product to satisfy demand, as much as $10 million in additional sales could quickly materialize, pushing Q2 sales to something "more like $95M," resulting in "a strong QQ jump ... based on normalization of inventory."Jefferies peer Stifel is similarly optimistic -- indeed, some of its comments sound even more optimistic than Yee, albeit Stifel's Derek Archila's price target ($27 with a 'buy' rating) is a bit more conservative than Yee's target of $30 (also with a 'buy rating'). (To watch the analysts' track records, click here)As Archila notes, Q1 is a seasonally weak quarter for Amarin, yet "script data ... over the first three weeks of the quarter" still showed RRx prescriptions up 52% year over year, TRx prescriptions up 62%, and NRx prescriptions growing 74%. Given the rapid rate of growth, Archila feels confident in raising its sales estimates for Amarin for this year to $375 million, and predicting 2020 sales of $600 million. Furthermore, the analyst raised its estimate for fiscal 2020 earnings -- the year in which it expects Amarin to turn profitable -- by 32%, to $0.45 per share."Vascepa is in the early innings of an accelerating growth phase," argues the analyst, and "it has only been a short time since the REDUCE-IT data were published." So the company's best years of growth may still lie ahead. In this regard, Archila notes that Health Canada granted Vascepa priority review last week, and there's still a chance the US Food and Drug Administration will follow suit.Archila adds that the Institute for Clinical and Economic Review (ICER) is reviewing the potential for using Vascepa "on top of other cardiovascular disease therapies," which could boost sales even further. While a positive outcome is not certain, Archila believes that given Vascepa's "relatively low cost," ICER could determine that administering Vascepa "is a highly cost-effective approach" to treating cardiovascular disease.Such a conclusion could be just the thing to turn this week's Amarin sellers into future buyers of the stock.Additional regulatory endorsements of Amarin's wares would make Archila's predictions of $375 million in 2019 sales (64% YOY growth) and $600 million in 2020 sales 60% growth more likely. As economies of scale begin kicking in, that would make even more exponential growth in profits more likely.Bottom lineAt $18 a share and 40 times estimated earnings two-years-from-now, Amarin stock doesn't look exactly cheap today. Still, with analysts predicting more than $2 a share in earnings by 2023, the stock's valuation looks increasingly more palatable the farther out you look. Many cannabis companies are making their way towards the medical sector as a source of inspiration to find the benefits of cannabis plant use for patients with various diseases. To read more on the nitty gritty of what’s going on in the rising cannabis industry, click here. More recent articles from Smarter Analyst: * Gene Munster: Key Takeaways From Nvidia (NVDA) Earnings * Trade War? Top Analyst Says Alibaba (BABA) Stock Still a Buy * The Green Organic Dutchman (TGODF) Stock -- Not Sinking Exactly, But Not Sailing Anywhere Fast * Is Boeing (BA) Stock a Buy Ahead of FAA Announcement?

  • Benzinga17 days ago

    5 Biotech Stocks With Near-Term Catalysts Ahead

    The biotechnology space is an exciting one with incredible potential for investors. One strategy that many have found success with in the biotech investing space is making moves around catalysts. This involves looking for companies with data readouts, PDUFA dates, and other upcoming releases that will likely move the needle for the stock.

  • Options Traders Expect Huge Moves in Amarin (AMRN) Stock
    Zacks17 days ago

    Options Traders Expect Huge Moves in Amarin (AMRN) Stock

    Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.

  • Why Amarin's Stock Sank on Strong First-Quarter Results
    Motley Fool17 days ago

    Why Amarin's Stock Sank on Strong First-Quarter Results

    Strong first-quarter numbers couldn't reverse Amarin's recent slide. Here's why.

  • Here's What You Need to Know From Amarin's Q1 Earnings Update
    Motley Fool18 days ago

    Here's What You Need to Know From Amarin's Q1 Earnings Update

    The small biotech continued to enjoy strong sales for Vascepa. But even better news could be on the way.

  • Amarin Corporation plc (AMRN) Q1 2019 Earnings Call Transcript
    Motley Fool18 days ago

    Amarin Corporation plc (AMRN) Q1 2019 Earnings Call Transcript

    AMRN earnings call for the period ending March 31, 2019.

  • Amarin (AMRN) Beats Estimates for Earnings & Revenues in Q1
    Zacks18 days ago

    Amarin (AMRN) Beats Estimates for Earnings & Revenues in Q1

    Amarin (AMRN) surpasses estimates for earnings and sales in the first quarter of 2019.

  • Associated Press18 days ago

    Amarin: 1Q Earnings Snapshot

    On a per-share basis, the Dublin-based company said it had a loss of 7 cents. Losses, adjusted for stock option expense, were 5 cents per share. The biopharmaceutical company posted revenue of $73.3 million ...

  • GlobeNewswire18 days ago

    Amarin Reports First Quarter 2019 Financial Results and Provides Update on Operations

    Total Revenue Increased 67% to $73.3 Million in First Quarter 2019 Compared to Prior Year Management to Host Conference Call at 7:30 a.m. ET Today BEDMINSTER, N.J., and.

  • 4 More Healthcare Earnings Reports to Watch This Week
    Motley Fool19 days ago

    4 More Healthcare Earnings Reports to Watch This Week

    If you thought Monday was exciting, wait until you see what's on the slate for the rest of the week.

  • GlobeNewswire20 days ago

    New Drug Submission Filed for Vascepa® with Health Canada

    Amarin Corporation plc (AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that its licensee in Canada, HLS Therapeutics Inc. (HLS.TO), has filed a New Drug Submission (“NDS”) with Health Canada for Vascepa® (icosapent ethyl) capsules. The NDS seeks an indication for promotion of Vascepa in Canada to reduce the risk of major adverse cardiovascular events (“MACE”) in statin-treated patients with elevated triglycerides and other risk factors.

  • What Kind Of Investor Owns Most Of Amarin Corporation plc (NASDAQ:AMRN)?
    Simply Wall St.24 days ago

    What Kind Of Investor Owns Most Of Amarin Corporation plc (NASDAQ:AMRN)?

    If you want to know who really controls Amarin Corporation plc (NASDAQ:AMRN), then you'll have to look at the makeup of its share registry. Generally speaking, as a company grows, institutions will increase their ownership. Convers...

  • Were Hedge Funds Right About Flocking Into Amarin Corporation plc  (AMRN) ?
    Insider Monkey25 days ago

    Were Hedge Funds Right About Flocking Into Amarin Corporation plc (AMRN) ?

    Is Amarin Corporation plc (NASDAQ:AMRN) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably but historically their consensus stock […]

  • What's in the Cards for Amarin (AMRN) This Earnings Season?
    Zacks25 days ago

    What's in the Cards for Amarin (AMRN) This Earnings Season?

    Amarin's (AMRN) cardiovascular drug, Vascepa to drive sales in the first quarter.

  • GlobeNewswire25 days ago

    Amarin To Report First Quarter 2019 Results and Host Conference Call On May 1, 2019

    Amarin Corporation plc (AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's first quarter 2019 financial results and provide an operational update on Wednesday, May 1, 2019 at 7:30 a.m. ET. The conference call can be heard live on the investor relations section of the company's website at www.amarincorp.com, or via telephone by dialing 877-407-8033 within the United States or 201-689-8033 from outside the United States.

  • GlobeNewswire26 days ago

    CLASS ACTION DEADLINE for CAG and AMRN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

    NEW YORK, April 23, 2019 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..

  • Business Wire26 days ago

    DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Amarin Corporation plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Amarin Corporation plc (“Amarin” or “the Company”) (NASDAQ: AMRN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

  • GlobeNewswire26 days ago

    CLASS ACTION UPDATE for AMRN, SYNH, WSR and FSNN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

    NEW YORK, April 23, 2019 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..

  • ACCESSWIRE26 days ago

    FINAL DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Amarin Corporation plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / April 19, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Amarin Corporation plc (''Amarin'' ...

  • ACCESSWIRE26 days ago

    CLASS ACTION UPDATE for AMRN, NTNX and BA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

    NEW YORK, NY / ACCESSWIRE / April 22, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders ...

  • GlobeNewswire27 days ago

    FINAL DEADLINE ALERT - AKRX, HIIQ & AMRN - Bronstein, Gewirtz & Grossman, LLC

    NEW YORK, April 22, 2019 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following.

  • ACCESSWIRE27 days ago

    SHAREHOLDER ALERT: AMRN BPI NTNX: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

    NEW YORK, NY / ACCESSWIRE / April 22, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you ...

  • GlobeNewswire27 days ago

    DEADLINE TUESDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Amarin Corporation plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Amarin Corporation plc (“Amarin” or “the Company”) (NASDAQ: AMRN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.